Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

Restricted access to genome-editing technologies poses serious challenges for countries like India that urgently need such ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.